We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Blood Test Predicts Diabetes Mellitus Type 1 Risk

By LabMedica International staff writers
Posted on 04 Jul 2013
Type 1 diabetes usually has a preclinical phase identified by circulating islet autoantibodies, but the rate of progression to diabetes after seroconversion to islet autoantibodies is equivocal.

Diabetes mellitus type 1 can occur at any age and it starts with the immune system destroying insulin-producing beta cells, which eventually stops the production of insulin and without insulin the body cannot control blood sugar or glucose. More...


Scientists based at the Helmholtz Zentrum (Munich, Germany) gathered data from three different studies, which included a total of 13,377 children. The study involved analyzing blood samples taken from children to identify any preclinical clues that indicate any increased risk of type 1 diabetes. Two diabetes-related autoantibodies were found to be the strongest indicators of diabetes risk.

The children’s genetic risk for type 1 diabetes was estimated by measuring the development of insulin autoantibodies, glutamic acid decarboxylase 65 (GAD65) autoantibodies, and insulinoma antigen 2 (IA2) autoantibodies. At the 10-year follow-up, an overwhelming 70% of the children with multiple islet autoantibodies developed type 1 diabetes, compared to 15% among those with just one autoantibody.

At follow-up, 8% of the children had one or more of the autoantibodies, indicators for the destruction of insulin, 585 children had at least two autoantibodies and 474 were found to have just one. Nearly half of the children with two or more autoantibodies went on to develop diabetes within five years, and four out of every five of them became diabetic within fifteen years. Only 14.5% of children with just one autoantibody developed type 1 diabetes after 10 years.

The authors concluded that the detection of multiple islet autoantibodies in children who are genetically at risk marks a preclinical stage of type 1 diabetes. Thus, the development of multiple islet autoantibodies in children predicts type 1 diabetes. Future prevention studies should focus on this high-risk population.

"Jay S. Skyler, MD, and Jay M. Sosenko, MD, both from the Leonard M. Miller School of Medicine (Miami, FL, USA) wrote in an accompanying editorial: "If you have two or more autoantibodies, it's nearly inevitable that you will develop the disease. Most people, even physicians, don't appreciate this risk." The study was published on June 19, 2013, in the Journal of the American Medical Association.

Related Links:
Helmholtz Zentrum
Leonard M. Miller School of Medicine



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Serological Pipet Controller
PIPETBOY GENIUS
New
DNA/RNA Extraction/Purification Kit
Nucleic Acid Extraction or Purification Kit
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.